Nektar Therapeutics Stock Analysis (NASDAQ:NKTR)

Add to My Stocks
$20.79 $0.71 (3.3%) NKTR stock closing price May 26, 2017 (Closing)
Watch Robo Advisor Video of NKTR Stock Analysis
Nektar Therapeutics
Updated on : May 25, 2017
previous close
NKTR 21.5 (0%)
S&P 500 2415.1 (0%)
Closing Price On: May 25, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Drugs
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q1
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
10.9%
Operating Profit
Operating Margin:
-120.2%
Sector Average:
1.1%
5 Quarter Net Profit
Net Margins
2017-Q1
%
LTM Margin
Debt/Equity Ratio
Debt:
248.4M
Debt/Equity Ratio:
 5.55
Compared to the industry
Cash Flow
Operating cash flow:
-$34.6M
Net Income:
-$63.9M
PROS      CONS
Long Term Growth
Recent Growth
Operating Margins
Net Margins
High Debt Burden
ROIC
ROE
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
NKTR PS :
25.2
Industry PS :
4.6
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-185%
Return on Equity:
-3880.2%
Free Cash Flow Margin:
-156.3%
Double Tap To Exit Full Screen
0:00
/

Nektar Therapeutics Analysis Video

86 5 2

View Nektar Therapeutics stock analysis video. This is our NKTR analyst opinion covering the buy and sell arguments for NKTR stock.

Nektar Therapeutics Stock Rating (2.3/5)

Our Nektar Therapeutics stock opinion is based on fundamentals of the company. This Nektar Therapeutics stock analysis is based on latest Q1 earnings for 2017. The stock price analysis takes into account a company's valuation metrics.

Should you buy NKTR stock?

  • Revenue growth has been tremendous with a compounded annual growth of 10.9% over the last 5 years.

Should you sell NKTR stock?

  • Nektar Therapeutics sales shrank by -58% year-over-year in 2017 Q1.
  • Nektar Therapeutics reported an average operating margin of -120.2% over the Last Twelve Months (LTM).
  • Over the last 12 months, Nektar Therapeutics had an average Net loss of -150.7%.
  • With a debt/equity ratio of  5.55, Nektar Therapeutics is highly leveraged in comparison to Medical peers.
  • PE ratio is meaningless for NKTR stock as the company has losses.
  • The company is trading at a price to sales multiple of 25.2, which is higher in comparison to the Medical-Drugs industry average of 4.6, making NKTR stock expensive.
  • Nektar Therapeutics has a negative ROIC (Return on Invested Capital) of -185%.
  • Nektar Therapeutics has a negative ROE (Return On Equity) of -3880.2%, indicating the company is not profitable.
  • The company has a negative free cash flow margin of -156.3%.

Comments on this video and Nektar Therapeutics stock